OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Asceneuron SA

2 Projects | 1 Researchers | $2,525,000 Invested

2020

Asceneuron SA

Dirk Beher, PhD

A single-center, randomized, placebo-controlled single and multiple ascending dose study in healthy male and female subjects to study the safety, tolerability, food effect, pharmacokinetics and target engagement of the second-generation O-GlcNAcase inhibitor ASN121151

  • Funding Amount: $2,200,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Tau
  • Status: Closed

2013

Asceneuron SA

Dirk Beher, PhD

O-GlcNAcase Inhibitors for Alzheimer's disease and Tauopathies

  • Funding Amount: $325,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Closed